|By PR Newswire||
|March 13, 2014 06:06 PM EDT||
BELLEVILLE, ON, March 13, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today held a conference call and audio webcast for its shareholders, at which time, Company representatives provided several corporate updates. The corporate presentation used during today's call/webcast is available on the Company's website (www.Bioniche.com) under Investors - Corporate Presentations.
Sale Transaction of Bioniche Animal Health to Vétoquinol
The Company outlined some of the terms of the sale transaction, the full details of which are available in the share purchase agreement filed on www.SEDAR.com.
The transaction is subject to approval by Bioniche shareholders at a Special Meeting on April 14, 2014 at 9:00 a.m. in Toronto, Ontario. If approved, the transaction could close on or about April 15, 2014. The Management Information Circular related to this meeting is now available on www.SEDAR.com and will be mailed to shareholders during the week of March 24, 2014. All shareholders are encouraged to vote in person or by proxy. Voting instructions will be contained in the Circular.
The Circular contains additional information about the proposed transaction, including a pro-forma perspective of the Company's financial position following the close of the deal and a fairness opinion from from specialized Canadian investment bank, Bloom Burton & Co.
"The Board of Directors and management of Bioniche Life Sciences Inc. believe it is in the best interests of the Company for shareholders to approve the proposed sale transaction to Vétoquinol," stated Dr. Michael Berendt, CEO of Bioniche Life Sciences Inc.
Vision for the Future
If the sale transaction is successfully concluded, the Company will have approximately 15 months of cash available to support its remaining business, which will ultimately be exclusively focused on human therapeutics with Urocidin™ for bladder cancer as the lead asset. The Company's global commercialization strategy for Urocidin™ is very much partnership-driven, and strategic partnering and licensing agreements will be sought to provide financing for further clinical and regulatory work that may be required for commercialization. Beyond Urocidin™, the Company will be looking for line extensions or therapeutic combinations that will further extend the value of the product and its underlying MCNA technology.
The Company will also be seeking out additional clinical stage or near-clinical stage therapeutic assets that can be brought into the business to broaden the human health portfolio and build on the Company's existing strengths in biologics, manufacturing and oncology.
Replay of Conference Call/Webcast
A replay of today's conference call will be available until March 20, 2014 at midnight by calling 1-855-859-2056 (passcode: 7767236).
Today's webcast will be available for replay using the following link
until March 13, 2015:
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative therapies for the global human health market. The Company's primary goal is to develop and commercialize products that advance human health and increase shareholder value. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE Bioniche Life Sciences Inc.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Mar. 24, 2017 12:15 PM EDT Reads: 1,310
Mar. 24, 2017 12:15 PM EDT Reads: 859
Mar. 24, 2017 12:00 PM EDT Reads: 1,565
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Mar. 24, 2017 12:00 PM EDT Reads: 1,793
Mar. 24, 2017 11:45 AM EDT Reads: 256
Mar. 24, 2017 11:30 AM EDT Reads: 3,258
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The in...
Mar. 24, 2017 10:55 AM EDT Reads: 283
Mar. 24, 2017 10:45 AM EDT Reads: 1,336
Mar. 24, 2017 10:45 AM EDT Reads: 10,536
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Mar. 24, 2017 10:00 AM EDT Reads: 176
Mar. 24, 2017 09:45 AM EDT Reads: 2,724
Mar. 24, 2017 09:45 AM EDT Reads: 2,662
Now that the world has connected “things,” we need to build these devices as truly intelligent in order to create instantaneous and precise results. This means you have to do as much of the processing at the point of entry as you can: at the edge. The killer use cases for IoT are becoming manifest through AI engines on edge devices. An autonomous car has this dual edge/cloud analytics model, producing precise, real-time results. In his session at @ThingsExpo, John Crupi, Vice President and Eng...
Mar. 24, 2017 08:45 AM EDT Reads: 3,617
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
Mar. 24, 2017 08:45 AM EDT Reads: 1,478
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, will discuss new ways of thinking and the approaches needed to address the emerging challenges of securit...
Mar. 24, 2017 08:30 AM EDT Reads: 4,216